Blog

The fight against pleural mesothelioma may find success in gene therapy. A research team from University Hospital in Zurich, Switzerland is working toward discovering the key to effective therapy for some mesothelioma sufferers. Genetic research in combating this cancer is not new, and while the results are promising here is one hurdle to cross. Using » Read More

Mesothelioma is an aggressive form of cancer caused by asbestos exposure. Pleural mesothelioma affects the lining, or pleura of the lungs and is difficult to detect in the early stages. Each year, about 3,000 people are diagnosed with pleural mesothelioma with a life expectancy between six and 18 months, largely because of late detection. At » Read More

Pembrolizumab, a drug that helps destroy cancer cells by working with the immune system, has been fully approved by the United States Food and Drug Administration (FDA). This is very good news for mesothelioma patients because clinical trials of the immunotherapy drug, marketed as Keytruda by Merck & Company, have shown considerable promise. One patient, » Read More

A group of researchers in the United Kingdom recently discovered a way to group patients in clinical trials in order to help determine success rates. In this case, the researchers were able to better predict a patient’s response to the clinical trial according to three biological factors. They are: The level of albumin in the » Read More